Optimi Health Corp.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a OPTI.CN research report →
Price Chart
About the company
Optimi Health Corp. focuses on developing an integrated brand of functional mushrooms specifically for the Canadian health and wellness food markets. The company manages the entire process from the cultivation and extraction to the processing and distribution of these mushroom strains.
- CEO
- Dane Stevens
- IPO
- 2021
- Employees
- 9
- HQ
- Princeton, BC, CA
Get TickerSpark's AI analysis on OPTI.CN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $21.48M
- P/E
- -3.42
- PEG
- 0.08
- P/S
- 122.27
- P/B
- 1.62
- EV/EBITDA
- -2.75
- Div Yield
- 0.00%
- Gross Margin
- -2092.20%
- Op Margin
- -3617.97%
- Net Margin
- -3927.59%
- ROE
- -84.23%
- ROIC
- -27.90%
Latest fiscal year · YoY change
- Revenue
- $426.30K+9.4%
- Gross Profit
- $-2,073,683-865.5%
- Op Income
- $-4,528,564
- Net Income
- $-3,712,031+38.5%
- EPS
- $-1.16+42.6%
- OCF Growth
- +38.6%
- FCF Growth
- +38.7%
- 52W High
- $12.60
- 52W Low
- $4.95
- 50D MA
- $6.57
- 200D MA
- $8.78
- Beta
- 1.59
- RSI (14)
- 49
- Avg Volume
- 8.30K
No earnings-call transcripts are available for OPTI.CN yet.
- Free Float
- 74.2%
- Shares Outstanding
- 3.22M
- Float Shares
- 2.39M
Our OPTI.CN coverage
Recent articles, reports, and earnings notes.
No research on OPTI.CN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate OPTI.CN report →Optimi Health Completes Psilocybin Export to Australia for Patients With Treatment-Resistant Depression
prnewswire.com · Jun 29
Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical Trial
prnewswire.com · Jun 10
Optimi Health Secures Ibogaine Supply and Commences Finished Drug Product Development
gurufocus.com · Jun 8
Optimi Health Secures Ibogaine Supply and Commences Finished Drug Product Development
prnewswire.com · Jun 8
Optimi Health Welcomes Expanded Psychedelic-Assisted Therapy Access Under Updated Authorized Prescriber Framework in Australia
gurufocus.com · May 29
Optimi Health Announces Pricing of Oversubscribed US$15 Million Public Offering and Nasdaq Uplisting
prnewswire.com · May 20
Optimi Health schließt Psilocybin-Export nach Australien zur Behandlung therapieresistenter Depression ab
feeds.newsfilecorp.com · Feb 19
Optimi Health meldet Beginn der ersten MDMA-gestützten Behandlungen im Jahr 2026 in einem erweiterten Netzwerk australischer Kliniken
feeds.newsfilecorp.com · Feb 16
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.